Joint Formulary & PAD

Ertugliflozin - Diabetes Mellitus

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
Empagliflozin is the preferred SGLT-2. Ertugliflozin is a treatment option. Trusts restrict to diabetic team initiation only.

PAD Profile

ChemicalSubstance :
Ertugliflozin
Indication :
Diabetes Mellitus
Group Name :
Keywords :
SGLT2s, SGLT2 inhibitors, sodium glucose co-transporter 2 inhibitors, diabetic ketoacidosis, DKA, SGL-T2s, oral antidiabetic drugs
Brand Names Include :
Steglatro
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
8

Other Indications

Below are listed other indications that Ertugliflozin is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Diabetes Mellitus.

Committee Recommendations (3)

The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.

The Surrey and North West Sussex Area Prescribing Committee (APC) recommends ertugliflozin as an option for the treating type 2 diabetes in line with NICE TA583
Ertugluiflozin (in combination) will be considered GREEN on the traffic light system

The Surrey and North West Sussex Area Prescribing Committee recommends ertugliflozin as monotherapy or with metformin as a treatment option in patients with type 2 diabetes in line with NICE TA572 (27 March 2019)

Ertugliflozin for this indication will be considered GREEN on the traffic light system.

Please note: There is currently no cardiovascular or renal outcome data available

See the Blood Glucose control treatment algorithm below for SGLT2 place in therapy